Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.44 |
| ▸ | BAD | Q92934 | 1/20 | 0.44 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | CA7 | P43166 | 1/20 | 0.38 |
| ▸ | CA9 | Q16790 | 1/20 | 0.38 |
| ▸ | ACHE | P22303 | 1/20 | 0.38 |
| ▸ | LPL | P06858 | 1/20 | 0.37 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.37 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.37 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | TXN | P10599 | 1/20 | 0.34 |
| ▸ | ERCC1 | P07992 | 1/20 | 0.34 |
| ▸ | ERCC4 | Q92889 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27051 | 0.90 | — | — | |
| SCHEMBL10300262 | 0.83 | BCL2L1 (0.55) | BCL2L1BADMAOBNPC1RAB9A | |
| SCHEMBL10337645 | 0.83 | BCL2L1 (0.55) | BCL2L1BADMAOBNPC1RAB9A | |
| SCHEMBL12562793 | 0.83 | BCL2L1 (0.55) | BCL2L1BADMAOBNPC1RAB9A | |
| SCHEMBL197346 | 0.83 | BCL2L1 (0.55) | BCL2L1BADMAOBNPC1RAB9A | |
| SCHEMBL4486299 | 0.75 | AGXT (0.47) | BCL2L1BAD | |
| SCHEMBL5543753 | 0.75 | TAAR1 (0.63) | CA9PTPN1NOTUMIDO1 | |
| SCHEMBL145806 | 0.75 | MAOB (0.52) | BCL2L1BADMAOBPTPN1IDO1 | |
| SCHEMBL5540625 | 0.75 | HSPB1 (0.48) | ALDH1A1HTT | |
| SCHEMBL6295435 | 0.75 | IDO1 (0.46) | MAOBALDH1A1IDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 108 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8338565-B2 | Macrocyclic compounds for inhibition of tumor necrosis factor alpha | ENSEMBLE THERAPEUTICS CORPORATION (US) | 2012-12-25 | — | — | US | claimed |
| EP-2350031-A2 | MACROCYCLIC COMPOUNDS FOR INHIBITION OF TUMOR NECROSIS FACTOR ALPHA | Ensemble Therapeutics Corporation (US) | 2011-08-03 | — | — | EP | claimed |
| US-20100152099-A1 | MACROCYCLIC COMPOUNDS FOR INHIBITION OF TUMOR NECROSIS FACTOR ALPHA | ENSEMBLE THERAPEUTICS CORPORATION | 2010-06-17 | — | — | US | claimed |
| WO-2010022249-A2 | MACROCYCLIC COMPOUNDS FOR INHIBITION OF TUMOR NECROSIS FACTOR ALPHA | ENSEMBLE DISCOVERY CORPORATION (US) | 2010-02-25 | — | — | WO | claimed |
| US-20030158428-A1 | Intermediates and processes for preparing substituted chromanol derivatives | PFIZER INC. | 2003-08-21 | — | — | US | claimed |
| CN-1108298-C | Process for preparing substituted chromanol derivatives | PFIZER (US) | 2003-05-14 | — | — | CN | claimed |
| CN-1394602-A | Benzoic acid substituted benzopyran fro curing atheroscleorsis | PFIZER (US) | 2003-02-05 | — | — | CN | claimed |
| EP-1270000-A2 | Benzoic acid substituted benzopyrans for the treatment of atherosclerosis | Pfizer Products Inc. (US) | 2003-01-02 | — | — | EP | claimed |
| WO-2002060888-A1 | PROCESSES FOR PREPARING CHROMANYLBENZOIC ACIDS | PFIZER PRODUCTS INC. (US) | 2002-08-08 | — | — | WO | claimed |
| EP-0943339-A2 | Method of preventing allograft rejection | Pfizer Products Inc. (US) | 1999-09-22 | — | — | EP | claimed |
| EP-0623123-B1 | Benzopyran and related LTB4-antagonists | PFIZER (US) | 1997-04-23 | — | — | EP | claimed |
| EP-0623122-B1 | Benzopyran and related LTB4-antagonists. | PFIZER (US) | 1997-03-05 | — | — | EP | claimed |
| US-5552435-A | ANTIINFLAMMATORY AGENTS, LEUKOTRIENE B4 ANTAGONISTS | PFIZER INC. (US) | 1996-09-03 | — | — | US | claimed |
| US-5550152-A | ANTIINFLAMMATORY AGENTS | PFIZER INC. (US) | 1996-08-27 | — | — | US | claimed |
| EP-0623122-A1 | BENZOPYRAN AND RELATED LTB 4? ANTAGONISTS. | PFIZER (US) | 1994-11-09 | — | — | EP | claimed |
| EP-0623123-A1 | BENZOPYRAN AND RELATED LTB4 ANTAGONISTS. | PFIZER (US) | 1994-11-09 | — | — | EP | claimed |
| CN-1075318-A | Chromene and relevant leukotriene B 4Antagonist | PFIZER (US) | 1993-08-18 | — | — | CN | claimed |
| WO-1993015066-A1 | BENZOPYRAN AND RELATED LTB4 ANTAGONISTS | PFIZER INC. (US) | 1993-08-05 | — | — | WO | claimed |
| WO-1993015067-A1 | BENZOPYRAN AND RELATED LTB4 ANTAGONISTS | PFIZER INC. (US) | 1993-08-05 | — | — | WO | claimed |
| CN-1074681-A | Chromene and relevant leukotriene B 4Antagonist | PFIZER (US) | 1993-07-28 | — | — | CN | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030158428-A1 | Intermediates and processes for preparing substituted chromanol derivatives | CYP1A1, CYP2F1, CYP7A1 | BCL2L1 3968/4885BAD 4518/4885MAOB 556/4885 |
| US-20100152099-A1 | MACROCYCLIC COMPOUNDS FOR INHIBITION OF TUMOR NECROSIS FACTOR ALPHA | TNF, CD40, TNFRSF1A | BCL2L1 366/4885BAD 32/4885MAOB 3068/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.